ANI PHARMACEUTICALS INC SEC Filings

ANI Pharmaceuticals Inc. senior vice president of generics Ori Gutwerg reported a sale of 3,162 shares of common stock on 2026-08-10 at $77.00 per share in an open market or private transaction. After this sale, he directly holds 75,534 shares of ANI Pharmaceuticals common stock.

ANI Pharmaceuticals reported stronger results for the quarter and six months ended June 30, 2026. For the quarter, net revenues were $266,044 thousand, up from $211,371 thousand a year earlier, and net income was $24,711 thousand versus $8,549 thousand. Operating income rose to $40,460 thousand from $13,892 thousand.

For the first half of 2026, total net revenues reached $503,506 thousand compared with $408,493 thousand in 2025, and net income increased to $54,203 thousand from $24,230 thousand. Rare Disease and Brands contributed $293,630 thousand, including Cortrophin Gel at $192,245 thousand, ILUVIEN and YUTIQ at $37,973 thousand, and brand royalties and other revenues at $39,271 thousand; Generics and Other contributed $209,876 thousand.

Liquidity improved, with cash and cash equivalents of $360,212 thousand at June 30, 2026 versus $285,585 thousand at year-end 2025 and net cash provided by operating activities of $115,044 thousand in the first half. The company carries Term Loan A borrowings of $304,688 thousand and 2.25% Convertible Senior Notes of $309,009 thousand (both in thousands). Retained earnings shifted to a positive $31,104 thousand from an accumulated deficit of $23,099 thousand at December 31, 2025.

ANI Pharmaceuticals reported record second-quarter 2026 results with total net revenues of $266.0 million, up 25.9% year-over-year. Rare Disease revenues rose to $135.8 million, including Cortrophin Gel net revenues of $117.1 million, an increase of 43.5%, while Generics net revenues grew 9.7% to $99.1 million.

GAAP net income available to common shareholders was $24.7 million, or $1.05 per diluted share, compared with $8.1 million and $0.36 a year earlier. Adjusted non-GAAP EBITDA increased 32.4% to $71.6 million and adjusted non-GAAP diluted EPS reached $2.21. The company reaffirmed 2026 guidance for total net revenue of $1,080–$1,140 million and adjusted non-GAAP EBITDA of $285–$300 million, while updating Cortrophin Gel net revenue guidance to $520–$540 million. As of June 30, 2026, ANI held $360.2 million in unrestricted cash and cash equivalents against $620.9 million of principal debt and had a $100.0 million share repurchase program authorized through May 2029.

ANI Pharmaceuticals SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on July 29, 2026 at a weighted average price of $81.36 per share in open-market or private transactions. The trades, priced between $80.61 and $81.88, were executed under a Rule 10b5-1 trading plan adopted on March 6, 2026. Following the sale, Carey directly holds 174,693 shares of ANI Pharmaceuticals common stock.

ANI Pharmaceuticals insider Stephen P. Carey filed a Form 144 for a proposed sale of common stock. The filing covers 6,163 shares of common stock held through Morgan Stanley Smith Barney LLC, with an aggregate market value of $499,449.52 and 22,734,618 shares of common stock outstanding as of this notice.

The securities to be sold relate to Restricted Stock Awards granted on April 6, 2019. The planned sale date is July 29, 2026 on NASDAQ. Over the prior three months, sales under a Rule 10b5-1 trading plan totaled 3,313 shares for $284,918.00 on July 2, 2026, 2,850 shares for $239,742.57 on June 29, 2026, and 3,312 shares for $264,960.00 on June 5, 2026.

ANI Pharmaceuticals Inc. is reported to have a significant shareholder, as BlackRock, Inc. has filed an amended beneficial ownership report. BlackRock’s reporting business units collectively beneficially own 2,899,843 shares of ANI Pharmaceuticals common stock, representing 12.8% of the outstanding class.

BlackRock reports sole voting power over 2,860,943 shares and sole dispositive power over 2,899,843 shares, with no shared voting or dispositive power. Various clients and other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of ANI’s outstanding common stock.

ANI Pharmaceuticals reported that executive Meredith Cook, Sr. VP, General Counsel & Secretary, had 2,466 shares of common stock withheld on July 18, 2026 to cover tax obligations, at $79.20 per share. The withholding related to the vesting of 4,820 restricted shares. Following this transaction, Cook directly holds 74,924 shares of ANI Pharmaceuticals common stock.

ANI Pharmaceuticals Inc. reported that senior vice president, general counsel and secretary Meredith Cook completed an open-market sale of 500 shares of common stock on July 13, 2026 at $81.84 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on September 15, 2025, and Cook now directly holds 77,390 shares of ANI Pharmaceuticals common stock.

ANIP: Form 144 filing reporting securities transactions by Patrick Walsh. The filing lists two reported dispositions of Common shares: 10,000 shares sold on 05/13/2026 for $806,300.00 and 3,973 shares sold on 05/11/2026 for $320,819.75. It also lists 4,336 restricted shares dated 05/22/2026 described as "Securities To Be Sold" with issuer indicated as the source.